ALLOGENE THERAPEUTICS INC
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
ALLOGENE THERAPEUTICS INC
Founded:
2017-01-01
Status:
Active
Email Addresses:
[email protected]
Total Funding:
120 M USD
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-02-10 | Notch Therapeutics | Allogene Therapeutics Inc investment in Series A - Notch Therapeutics | 85 M USD |
| 2019-11-06 | Notch Therapeutics | Allogene Therapeutics Inc investment in Corporate Round - Notch Therapeutics | 1000 K USD |
More informations about "Allogene Therapeutics Inc"
Allogene Therapeutics - Crunchbase Company Profile & Funding
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.See details»
Allogene Therapeutics, Inc. (ALLO) - Yahoo Finance
See the company profile for Allogene Therapeutics, Inc. (ALLO) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Allogene Therapeutics (ALLO) Company Profile & Description
Oct 11, 2018 Company profile for Allogene Therapeutics, Inc. (ALLO) stock, with a description, list of executives, contact details and other key facts.See details»
Allogene Therapeutics Inc: Overview - GlobalData
Up-to-date Allogene Therapeutics Inc company overview including funding information, company profile, key statistics, peer comparison and more.See details»
Allogene Therapeutics, Inc. - AnnualReports.com
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR Tâ„¢) therapies for cancer. Led by a …See details»
Allogene Therapeutics - The Org
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR Tâ„¢) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: …See details»
Allogene Therapeutics - 2025 Company Profile & Team - Tracxn
Aug 3, 2025 Explore Allogene Therapeutics' in-depth company profile, including funding details, key investors, leadership, competitors, and acquisitions.See details»
Allogene Therapeutics, Inc. (ALLO) Business Profile — stockrow
Jan 11, 2025 Explore a detailed business profile of Allogene Therapeutics, Inc. (ALLO), a leader in allogeneic CAR T-cell therapies for cancer treatment. Learn about its innovative technology, …See details»
Allogene Therapeutics 2025 Company Profile: Stock …
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the …See details»
Home - Allogene
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and AustraliaSee details»
Allogene Therapeutics, Inc.
Our off-the-shelf approach is dependent on state-of-the-art manufacturing processes, and we are building a technical operations organization with fully integrated in-house expertise in clinical …See details»
Company: Allogene Therapeutics - crisprmedicinenews.com
Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR Tâ„¢) …See details»
Investor Relations | Allogene Therapeutics
The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.See details»
Allogene Therapeutics Reports Second Quarter 2025 ... - Seeking …
2 days ago Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update Aug. 13, 2025 4:05 PM ET Allogene Therapeutics, Inc. (ALLO)See details»
Allogene Therapeutics, Inc. (ALLO) - Yahoo Finance
Jan 29, 2019 See the company profile for Allogene Therapeutics, Inc. (ALLO) including business summary, industry/sector information, number of employees, business summary, corporate …See details»
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights ...
2 days ago Allogene Therapeutics Inc (NASDAQ:ALLO) has made significant advancements across its portfolio, including progress in the ALPHA3 study for large B-cell lymphoma and the …See details»
Allogene Therapeutics Reports Second Quarter 2025 Financial …
2 days ago SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the …See details»
Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript
1 day ago Allogene Therapeutics discusses Q2 2025 milestones and pipeline updates, including notable progress in CAR T-cell therapy for cancer and autoimmune diseases.See details»
Allogene Therapeutics Reports Second Quarter 2025 Financial …
2 days ago SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the …See details»
Form 10-K for Allogene Therapeutics INC filed 03/13/2025
5 lymphodepletion regimen. Our off-the-shelf approach is dependent on state-of-the-art manufacturing processes, and we believe we have built a technical operations organization …See details»